NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors

Nano Research

Volumn 9, Issue 5, 2016, Pages 1393-1408

  Curnis, Flavio ^a   Fiocchi, Martina ^a   Sacchi, Angelina ^a   Gori, Alessandro ^b   Gasparri, Anna ^a   Corti, Angelo ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

albumin; Asn Gly Arg (NGR); CD13; gold nanoparticles; integrin; isoAsp Gly Arg (isoDGR); tumor necrosis factor

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; ENDOTHELIAL CELLS; FIBER OPTIC SENSORS; GLYCOPROTEINS; GOLD NANOPARTICLES; LIGANDS; MACROPHAGES; MAMMALS; MEDICAL NANOTECHNOLOGY; METAL NANOPARTICLES; TUMORS;

ALBUMIN; ASN-GLY-ARG (NGR); CD13; INTEGRINS; ISOASP-GLY-ARG (ISODGR); TUMOR NECROSIS FACTORS;

TARGETED DRUG DELIVERY;

EID: 84960417875     PISSN: 19980124     EISSN: 19980000     Source Type: Journal    
DOI: 10.1007/s12274-016-1035-8     Document Type: Article

References (31)

1. Curnis, F.; Sacchi, A.; Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest.2002, 110, 475–482.
2. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol.2000, 18, 1185–1190.
3. Curnis, F.; Gasparri, A.; Sacchi, A.; Cattaneo, A.; Magni, F.; Corti, A. Targeted delivery of IFN? to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res.2005, 65, 2906–2913.
4. Curnis, F.; Gasparri, A.; Sacchi, A.; Longhi, R.; Corti, A. Coupling tumor necrosis factor-a with aV integrin ligands improves its antineoplastic activity. Cancer Res.2004, 64, 565–571.
5. Gregorc, V.; Zucali, P. A.; Santoro, A.; Ceresoli, G. L.; Citterio, G.; De Pas, T. M.; Zilembo, N.; De Vincenzo, F.; Simonelli, M.; Rossoni, G. et al. Phase IIstudy of asparagineglycine- arginine-human tumor necrosis factor a, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol.2010, 28, 2604–2611.
6. Gregorc, V.; Citterio, G.; Vitali, G.; Spreafico, A.; Scifo, P.; Borri, A.; Donadoni, G.; Rossoni, G.; Corti, A.; Caligaris-Cappio, F. et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer2010, 46, 198–206.
7. Corti, A.; Curnis, F.; Rossoni, G.; Marcucci, F.; Gregorc, V. Peptide-mediated targeting of cytokines to tumor vasculature: The NGR-hTNF example. BioDrugs2013, 27, 591–603.
8. Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; Mirkin, C. A. Gold nanoparticles for biology and medicine. Angew. Chem., Int. Ed.2010, 49, 3280–3294.
9. Cai, W. B.; Gao, T.; Hong, H.; Sun, J. T. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol. Sci. Appl.2008, 1, 17–32.
10. Paciotti, G. F.; Myer, L.; Weinreich, D.; Goia, D.; Pavel, N.; McLaughlin, R. E.; Tamarkin, L. Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv.2004, 11, 169–183.
11. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res.2010, 16, 6139–6149.
12. Powell, A. C.; Paciotti, G. F.; Libutti, S. K. Colloidal gold: A novel nanoparticle for targeted cancer therapeutics. Methods Mol. Biol.2010, 624, 375–384.
13. Meng, J.; Yan, Z.; Wu, J.; Li, L.; Xue, X.; Li, M.; Li, W.; Hao, Q.; Wan, Y.; Qin, X. et al. High-yield expression, purification and characterization of tumor-targeted IFN-a2a. Cytotherapy2007, 9, 60–68.
14. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R. A.; Shapiro, L. H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res.2000, 60, 722–727.
15. Curnis, F.; Arrigoni, G.; Sacchi, A.; Fischetti, L.; Arap, W.; Pasqualini, R.; Corti, A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res.2002, 62, 867–874.
16. Di Matteo, P.; Arrigoni, G. L.; Alberici, L.; Corti, A.; Gallo-Stampino, C.; Traversari, C.; Doglioni, C.; Rizzardi, G. P. Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues. J. Histochem. Cytochem.2011, 59, 47–59.
17. Curnis, F.; Longhi, R.; Crippa, L.; Cattaneo, A.; Dondossola, E.; Bachi, A.; Corti, A. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J. Biol. Chem.2006, 281, 36466–36476.
18. Curnis, F.; Cattaneo, A.; Longhi, R.; Sacchi, A.; Gasparri, A. M.; Pastorino, F.; Di Matteo, P.; Traversari, C.; Bachi, A.; Ponzoni, M. et al. Critical role of flanking residues in NGRto- isoDGR transition and CD13/integrin receptor switching. J. Biol. Chem.2010, 285, 9114–9123.
19. Curnis, F.; Sacchi, A.; Gasparri, A.; Longhi, R.; Bachi, A.; Doglioni, C.; Bordignon, C.; Traversari, C.; Rizzardi, G. P.; Corti, A. Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif. Cancer Res.2008, 68, 7073–7082.
20. Corti, A.; Curnis, F. Isoaspartate-dependent molecular switches for integrin-ligand recognition. J. Cell Sci.2011, 124, 515–522.
21. Spitaleri, A.; Mari, S.; Curnis, F.; Traversari, C.; Longhi, R.; Bordignon, C.; Corti, A.; Rizzardi, G. P.; Musco, G. Structural basis for the interaction of isoDGR with the RGD-binding site of avß3 integrin. J. Biol. Chem.2008, 283, 19757–19768.
22. Frank, A. O.; Otto, E.; Mas-Moruno, C.; Schiller, H. B.; Marinelli, L.; Cosconati, S.; Bochen, A.; Vossmeyer, D.; Zahn, G.; Stragies, R. et al. Conformational control of integrinsubtype selectivity in isoDGR peptide motifs: A biological switch. Angew. Chem., Int. Ed.2010, 49, 9278–9281.
23. Bochen, A.; Marelli, U. K.; Otto, E.; Pallarola, D.; Mas-Moruno, C.; Di Leva, F. S.; Boehm, H.; Spatz, J. P.; Novellino, E.; Keßsler, H. et al. Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes a5ß1 and avß6: Conformational control through flanking amino acids. J. Med. Chem.2013, 56, 1509–1519.
24. Curnis, F.; Sacchi, A.; Longhi, R.; Colombo, B.; Gasparri, A.; Corti, A. IsoDGR-tagged albumin: A new avß3 selective carrier for nanodrug delivery to tumors. Small2013, 9, 673–678.
25. Curnis, F.; Corti, A. Production and characterization of recombinant human and murine TNF. Methods Mol. Med.2004, 98, 9–22.
26. Dondossola, E.; Rangel, R.; Guzman-Rojas, L.; Barbu, E. M.; Hosoya, H.; St John, L. S.; Molldrem, J. J.; Corti, A.; Sidman, R. L.; Arap, W. et al. CD13-positive bone marrowderived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. USA2013, 110, 20717–20722.
27. Wong, A. H. M.; Zhou, D. X.; Rini, J. M. The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing. J. Biol. Chem.2012, 287, 36804–36813.
28. Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Unraveling the mysteries of serum albumin-more than just a serum protein. Front. Physiol. 2014, 5, 299.
29. Colombo, G.; Curnis, F.; De Mori, G. M. S.; Gasparri, A.; Longoni, C.; Sacchi, A.; Longhi, R.; Corti, A. Structureactivity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem.2002, 277, 47891–47897.
30. Liu, C.; Yang, Y.; Chen, L.; Lin, Y. L.; Li, F. A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy. J. Biol. Chem.2014, 289, 34520–34529.
31. Fields, G. B.; Noble, R. L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res.1990, 35, 161–214.